As the DeSantis administration rails against the FDA decision to limit use of monoclonal antibody treatments made by Regeneron and Eli Lilly, worth noting both companies say they agree with the feds that these drugs aren’t effective against omicron.
— Daniel Dale (@ddale8) January 25, 2022
Regeneron left, Lilly right: https://t.co/3QWxqDC4zC pic.twitter.com/3vDj4ojWjm